Colorectal Cancer Therapeutics Market Outlook:
Colorectal Cancer Therapeutics Market size was over USD 12.77 billion in 2024 and is poised to exceed USD 20.41 billion by 2034, witnessing over 4.8% CAGR during the forecast period i.e., between 2025-2034. In the year 2025, the industry size of colorectal cancer therapeutics is estimated at USD 13.29 billion.
Key Colorectal Cancer Therapeutics Market Insights Summary
North America region is anticipated to hold the highest revenue share by 2037.
Targeted Therapy Segment is expected to witness substantial growth within the colorectal cancer therapeutics market through to 2037.
Key Growth Drivers:
- Worldwide Increasing Prevalence of Cancer
- Emerging Novel Therapies for Cancer Treatment
- Significant Research on Novel Drugs
- Global Surge in Geriatric Population
- Escalation in Worldwide Healthcare Expenditure
Key Players:
- Novartis AG, Pfizer Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Bayer AG, Amgen Inc., Genentech, Inc.,Teva Pharmaceuticals Industries Ltd., Ipsen Biopharmaceuticals, Inc.
Market Size and Growth Projections
- 2024 Market Size: USD 12.77 billion
- 2025 Market Size: USD 13.29 billion
- Projected Market Size: USD 20.41 billion by 2034
- Growth Forecasts: 4.8% CAGR (2025-2034)
- Largest Region: North America
- Fastest Growing Region: North America
The market growth is attributed to rising prevalence of colorectal cancer across the globe, increasing awareness of the serious impacts of colorectal cancer, and growing diagnostic methods. For instance, nearly 2.3 million cases of colorectal cancer were diagnosed in 2020, making it the third most prevalent cancer type worldwide.
Further, systematic treatments include chemotherapy, targeted therapy, and immunotherapy. Rising awareness in people regarding cancer, and increasing count of colorectal cancer screenings are robustly driving the market expansion. It is observed that every year, more than 16 million colonoscopies are conducted in the United States.
Colorectal Cancer Therapeutics Market Growth Drivers and Challenges:
Growth Drivers
- Worldwide Increasing Prevalence of Cancer - Cancer is a broad term that refers to a wide range of diseases that affect any part of the body. Cancer occurs when the body’s cells develop in an uncontrolled way and spread to other parts of the body. Currently, cancer is a leading cause of death across the globe. As per the World Health Organization (WHO) data, in 2020, nearly 10 million people died from cancer across the globe. Therefore, the increasing prevalence of cancer is leading to the growth of the colorectal cancer therapeutics market.
- Emerging Novel Therapies for Cancer Treatment – For instance, CRISPR is a new CAR T-cell therapy, which involves genetically engineering a patient's T-cells (a type of white blood cell) to fight cancer. As a potential new cancer treatment technology, gene editing with CRISPR takes months rather than a year or two to mutate T cells. Patients are anticipated to benefit from much faster treatment as a result of this.
- Significant Research on Novel Drugs – It has been observed in a recent short clinical trial, the investigational medicine dostarlimab completely cured all 18 patients of rectal cancer.
- Global Surge in Geriatric Population - According to the data released by the World Health Organization, the global population of people aged 60 and over is projected to rise from 1 billion in 2020 to 1.4 billion by 2030. The world's population of people aged 60 and up is expected to double to 2.1 billion by 2050.
- Escalation in Worldwide Healthcare Expenditure – As per the World Bank, in 2019, the global healthcare expenditure expanded by 9.83% of total GDP. This represents an increase from 2017, while the global healthcare expenditure accounted for 9.77% of the total GDP.
Challenges
- High Cost of Cancer Drugs- Cancer drugs need a new variety of APIs as the patient develops resistance to the old drugs owing to long-term treatment methods. Cancer can be of different types in different areas in the same person. Also, there are other medications required to treat the side effects of cancer disease that hampers the market growth.
- Concern for Adverse Effect Associated with the Treatment
- Long Term Procedures of Cancer Treatments
Colorectal Cancer Therapeutics Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2034 |
|
CAGR |
4.8% |
|
Base Year Market Size (2024) |
USD 12.77 billion |
|
Forecast Year Market Size (2034) |
USD 20.41 billion |
|
Regional Scope |
|
Colorectal Cancer Therapeutics Market Segmentation:
Therapy Segment Analysis
The targeted therapy segment is projected to significantly grow in the colorectal cancer therapeutics market through 2034, on the back of its highly effective and lifesaving functions, and increasingly sophisticated therapeutics. For instance, chemotherapy sessions offer only around a 25% chance of success, whereas targeted therapy is close to 75% effective.
Our in-depth analysis of the global market includes the following segments:
|
By Therapy |
|
|
By Cancer Type |
|
|
By Application |
|
|
By End-User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportColorectal Cancer Therapeutics Market Regional Analysis:
North America Market Insights
The North America region colorectal cancer therapeutics market is expected to account for largest revenue share by the end of 2034. The market growth is impelled by escalating incidences of colorectal cancer coupled with supportive government initiatives, rising healthcare expenditure, rising number of colon cancer, and increasing awareness among people regarding the screening of colorectal cancer. For instance, the third most prevalent cancer in the United States is colorectal cancer. Around 105,280 new cases of colon cancer and 45,760 new cases of rectal cancer are estimated to be diagnosed in 2022.
Key Colorectal Cancer Therapeutics Market Players:
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- Bayer AG
- Amgen Inc.
- Genentech, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Ipsen Biopharmaceuticals, Inc.
Recent Developments
- Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme Inc. and expanded its oncology portfolio.
-
Novartis AG announced the promising clinical data for its investigational KRASG12C inhibitor JDQ443, an investigational selective, covalent, and orally bioavailable inhibitor at the annual meeting of the American Association for Cancer Research (AACR)
Author Credits: Radhika Pawar
- Report ID: 436
- Published Date: Jun 13, 2025
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Copyright @ 2025 Research Nester. All Rights Reserved.
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
See our insights in action - schedule your demo now!